{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967783",
  "id": "02967783",
  "pages": 7,
  "price_sensitive": false,
  "date": "20250709",
  "time": "1235",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmwxjgz3qcrk.pdf",
  "summary": "### **Capital Raising Announcement Summary**  \n\n- **Structure**: Placement with attaching options (Tranche 2)  \n- **Total Capital Raised**: Not explicitly stated (refer to 26 May 2025 announcement for total ~$8.7M)  \n- **Key Dates**:  \n  - Shareholder approval obtained at EGM (8 July 2025)  \n  - **Issue date**: 11 July 2025  \n- **Details**:  \n  - **Ordinary Shares Issued**: 2,877,071 (post-1:400 consolidation) at **A$1.20/share**  \n  - **Options Issued**:  \n    - 5,833,334 attaching to placement (exercise **A$0.003**, expiry **31-Jul-2027**)  \n    - 354,332 adviser/shortfall options (same terms)  \n- **Use of Funds**: Clinical trials, working capital, offer costs  \n- **Broker Fee**: 6% of funds raised + 187,665 options (post-consolidation)  \n\n*No material changes to capital structure beyond disclosed terms.*",
  "usage": {
    "prompt_tokens": 2964,
    "completion_tokens": 236,
    "total_tokens": 3200,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T03:16:41.667683"
}